A standard regimen for estrogen receptor (ER)-negative breast cancer patients, accounting for 30% of breast cancer patients, is paclitaxel (P), doxorubicin (A), and cyclophosphamide (C) neoadjuvant chemotherapy (NAC) (Jemal et al., 2011). Here, ESR1 is linked to breast carcinoma.